Annals of Oncology Advance Access originally published online on May 13, 2005
Annals of Oncology 2005 16(7):1140-1146; doi:10.1093/annonc/mdi212
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer
Departments of 1 Medical Oncology, 2 Radiotherapy and 3 Surgery, Padova University Hospital, Padova; 4 Clinical Epidemiology Unit, Regional Cancer Centre, Padova University Hospital, Padova; 5 Department of Medical Oncology and Cancer Prevention, E. O. Ospedali Galliera, Genova, Italy
* Correspondence to: Dr C. Aschele, Department of Medical Oncology and Cancer Prevention, E. O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genova, Italy. Tel: +39-010-5634502; Fax: +39-010-5634500; Email: aschele{at}tin.it
Background: Oxaliplatin (OXA) significantly enhanced the antitumour activity of 5-fluorouracil (FUra) in patients with advanced colorectal cancer and displayed radiosensitising properties in preclinical studies. This study was thus performed to test the feasibility, identify the recommended doses (RDs) and explore preliminarily the clinical activity of weekly OXA and infused FUra combined with preoperative pelvic radiotherapy.
Patients and methods: Forty-six patients with recurrent or locally advanced (cT3-4 and/or N+) adenocarcinomas of the mid-low rectum were treated with escalating doses of OXA (25, 35, 45, 60 mg/m2, weekly for 6 weeks) and FUra (200–225 mg/m2/day, 6-week infusion) concurrent to preoperative pelvic radiotherapy (50.4 Gy/28 fractions). The RDs for the phase II part of the study were immediately below the level resulting in dose-limiting toxicities in more than one third of the patients, or corresponded to the last planned dose level.
Results: In the escalation phase, dose-limiting toxicities only occurred in one patient at the fourth level and one of six patients treated at the last planned dose level (grade III diarrhoea). OXA 60 mg/m2 and FUra 225 mg/m2/day are therefore the RDs for the regimen. Among 25 patients globally treated at these doses (phase II part), the incidence of grade III diarrhoea was 16% with no grade IV toxicity. Neurotoxicity did not exceed grade II (12%). All patients completed radiotherapy and were operated on as scheduled. Twenty-one of 25 patients had the tumour down-staged after chemoradiation with seven (28%) pathological complete responses and 12 (48%) residual tumours limited to ypT1-2N0.
Conclusions: Weekly OXA, at doses potentially active systemically, can be combined with full-dose, infused FUra and radiotherapy. Given the low toxicity and promising activity, this regimen is being compared to standard FUra-based pelvic chemoradiation in a randomised study.
Key words: 5-fluorouracil, neoadjuvant chemoradiation, oxaliplatin, phase I–II study, rectal cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Moureau-Zabotto, J.-M. Phelip, P. Afchain, L. Mineur, T. Andre, V. Vendrely, G. Lledo, O. Dupuis, F. Huguet, E. Touboul, et al. Concomitant Administration of Weekly Oxaliplatin, Fluorouracil Continuous Infusion, and Radiotherapy After 2 Months of Gemcitabine and Oxaliplatin Induction in Patients With Locally Advanced Pancreatic Cancer: A Groupe Coordinateur Multidisciplinaire en Oncologie Phase II Study J. Clin. Oncol., March 1, 2008; 26(7): 1080 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodel Radiation Therapy Combined with Novel Chemotherapy Regiments and Targeted Agents for Patients with Rectal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 146 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Willett, B. G. Czito, and J. C. Bendell Radiation Therapy in Stage II and III Rectal Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6903s - 6908s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Aschele and S. Lonardi Multidisciplinary treatment of rectal cancer: medical oncology. Ann. Onc., November 1, 2007; 18(11): 1908 - 1915. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Hospers, C. J. A. Punt, M. E. Tesselaar, A. Cats, K. Havenga, J. W. H. Leer, C. A. Marijnen, E. P. Jansen, H. H. J. M. Van Krieken, T. Wiggers, et al. Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I II Multicenter Study of the Dutch Colorectal Cancer Group Ann. Surg. Oncol., October 1, 2007; 14(10): 2773 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Sharma, G. A. Van Hazel, B. Morgan, D. P. Berry, K. Blanshard, D. Price, G. Bower, J. A. Shannon, P. Gibbs, and W. P. Steward Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy J. Clin. Oncol., March 20, 2007; 25(9): 1099 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Aschele and S. Lonardi Addition of Weekly Oxaliplatin to Standard Preoperative Chemoradiation for Locally Advanced Rectal Cancer J. Clin. Oncol., February 10, 2007; 25(5): 602 - 603. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Ryan, D. Niedzwiecki, D. Hollis, J. Tepper, and R. J. Mayer In Reply J. Clin. Oncol., February 10, 2007; 25(5): 603 - 603. [Full Text] [PDF]
|
|
|
|
|
|
T. Watanabe, T. Kiyomatsu, T. Kanazawa, Y. Kazama, T. Kojima, J. Tanaka, T. Tanaka, and H. Nagawa Weekly oxaliplatin and preoperative radiotherapy as a new neoadjuvant therapy for locally-advanced rectal cancer Ann. Onc., July 1, 2006; 17(7): 1173 - 1173. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Calvo, F. J. Serrano, J. A. Diaz-Gonzalez, M. Gomez-Espi, E. Lozano, R. Garcia, D. de la Mata, J. A. Arranz, P. Garcia-Alfonso, G. Perez-Manga, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation Ann. Onc., July 1, 2006; 17(7): 1103 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Aschele, M. L. Friso, P. Del Bianco, and S. Pucciarelli Reply to Letter to the Editor 'Weekly oxaliplatin and pre-operative radiotherapy as a new neoadjuvant therapy for locally advanced rectal cancer', by T. Watanabe et al. (Ann Oncol 2006; 17: 1173) Ann. Onc., July 1, 2006; 17(7): 1173 - 1174. [Full Text] [PDF]
|
|
|
|
|
|
I. Chau, G. Brown, D. Cunningham, D. Tait, A. Wotherspoon, A. R. Norman, N. Tebbutt, M. Hill, P. J. Ross, A. Massey, et al. Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer J. Clin. Oncol., February 1, 2006; 24(4): 668 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. De Paoli, S. Chiara, G. Luppi, M. L. Friso, G. D. Beretta, S. Del Prete, L. Pasetto, M. Santantonio, E. Sarti, G. Mantello, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study Ann. Onc., February 1, 2006; 17(2): 246 - 251. [Abstract] [Full Text] [PDF]
|
|